anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To provide a health-promoting agent by extracting semifermented tea with an alcohol, purifying the extract, and using the obtained tea saponin as a main component. CONSTITUTION:The leaf, stalk, seed and/or fruit of semifermented tea (e.g. oolong tea, TETSUKANNON, TOCHO oolong tea, KISHU tea, HOSHU tea, flower tea, etc., all are varieties of oolong tea) are defatted with a large amount of fat-dissolving organic solvent (e.g. n-hexane, ether, benzene, ethyl acetate, etc.) preferably under heating. The obtained tea is swollen with hot water preferably at 6.0pH, and extracted with a lower aliphatic alcohol. The solvent is distilled off from the extract at &lt;=100 deg.C under reduced pressure. The resultant extract is partitioned with water and n-butanol and the solvent is distilled off from the butanol layer, or the extract is dissolved in water and adsorbed with a polystyrene resin. The tea saponin obtained by distilling off the solvent is used as a main component of the present health-promoting agent which is extremely effective as a reducing and beautifying drug.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a preparation containing liposome effectively containing a water soluble compound.  &lt;P&gt;SOLUTION: The preparation containing liposome includes liposome preferably containing a nonionic iodine based compound and at least one biologically permissible auxiliary agent for the preparation in internal and external water phase of a lipid membrane. The liposome is produced in a supercritical carbon dioxide method and substantially comprises 1-10 sheets of lipid membrane and 70% of the liposome is composed of 2-some number of sheets of lipid membrane. The rate of inclusion of the compound in the liposome is 25-35%. The liposome membrane constituting component comprises at least a phospholipid having a polyethylene glycol group, having 40-70°C of melting points and substantially free from organic solvents and used as the X-ray contrast medium.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To provide a cosmetic base having an indicator function for moisture content, or such a function capable of changing the colors and patterns in makeup, comprising powder of specified characteristics and a binder resin. CONSTITUTION:The objective cosmetic base comprising (A) 20-80wt.% of powder &lt;=2.0 in refractive index and &lt;=20mum in average particle size (e.g silica) and (B) 5-30wt.% of a binder resin. For the binder resin, it is preferable that the resin itself be highly transparent, and when made into a film, the film be water- penetrable and water-resistant (e.g. polyethylene vinyl acetate resin, or a mixture thereof). The present cosmetic base may be additionally incorporated, where appropriate, with colorant, oil component, humectant, ultraviolet light absorber, antifungal agent, perfume, etc. The present cosmetic base differs in transparency in the case when dried, compared to the case when got wet, and when coated, being opaque in a dried state, and getting translucent or transparent when incorporated with water, leading to change in color tone.
The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of &gt;81%, preferably &gt;90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemical purification method or preferably with a purification method involving less column chromatography. The monoclonal antibodies thus produced are suitable, in gamma-irradiated form, e.g. Tc-99m labelled, for the in vivo diagnosis of inflammatory diseases and bone marrow metastases. In alpha - or beta-irradiated form, e.g. astatine or Re-188 or Y-90 labelled form, the inventive monoclonal antibodies can be used, for example, in the treatment of leukemia.
A method of preparing a transgenic animal model with enhanced, accelerated pathology for Alzheimer&#39;s Disease (AD) and the transgenic animal made by the method is disclosed. The method includes producing an F1 generation by crossing a first and second transgenic parent each carrying a different expressible transgene for differing aspects of the same desired phenotype associated with AD pathology. The offspring of the F1 generation are then screened and those which carry a transgene from each parental transgenic animal resulting in an enhanced pathology for Alzheimer&#39;s Disease are selected. In a preferred embodiment the AD-associated pathology is for amyloid accumulation. In an embodiment a mutant presenilin transgene and a transgene for a mutant amyloid precursor protein are used. In a further embodiment the mutant presenilin transgene is the PS1 M146L mutation and the mutant amyloid precursor protein transgene is the Swedish mutation (APP695 isoform containing a K670N,M671L mutation (APP770 numbering)).
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a lipid peroxide eliminator which can eliminate a produced lipid peroxide to remove adverse effects caused by the lipid peroxide.  &lt;P&gt;SOLUTION: This lipid peroxide eliminator is characterized by containing an electron-imparting anti-oxidizing substance and a peroxidase. The electron-imparting anti-oxidizing substance preferably comprises one or more of ascorbic acid, polyphenol compounds, quercetin, capsaicine, caffeic acid, guaiacol, and propyl gallate. The lipid peroxide eliminator exhibits a more excellent lipid peroxide-eliminating action than those of conventional anti-oxidizing agents and glutathione system compounds, when added to a target such as a food, a cosmetic composition or a medicine composition. Also, the lipid peroxide eliminator inhibits the deterioration of a quality due to the lipid peroxide, and can improve storability and stability.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
501,732. Cosmetics. FACTOR &amp; CO., M. June 23, 1937, No. 17498. Convention date, Nov. 27, 1936. [Class 81 (i)] Cosmetics in dry solid cake form are prepared by forming an oil-in-water emulsion of oils, waxes and water-soluble dispersing agent in a large volume of water, adding from 0&#39;76 to 1-25 parts of fillers and pigments to one part of emulsion, drying the mixture and compressing it into cake form. According to an example, 12 parts of a mixture containing 80 per cent olive oil or petroleum oil, 2À25 per cent paraffin wax or beeswax, 13À5 per cent stearic or oleic acid, 1À34 per cent triethanolamine, 0À66 per cent potassium or sodium hydroxide, and 2À24 per cent lauryl or cetyl alcohol is mixed with 8 parts of diethylene glycol, and is emulsified with 60 parts of water and 50 parts of aqueous quince seed extract and the whole is mixed with 0À75 to 1À2 parts of pigments, colours and fillers to each part of emulsion. The proportions of the ingredients may be varied particularly where a cosmetic of reduced masking effect or one to give a shiny effect is required. The cosmetic is applied by means of a wet sponge and is stated to be waterproof in use but to be removable by rubbing with soap and water. In the composition specified above, the oils may be replaced by vegetable or animal oils, benzoinated lard or hydrogenated products ; paraffin wax may be replaced by vegetable or animal waxes ; the dis. persing agents may be replaced by soap, lanoline (Registered Trade Mark), sulphonated alcohols or glycerin ; quince seed extract may be replaced by gum tragacanth, gum karaya, gum acacia, agar, or pectin, and talc may be used as the filler. Reference has been directed by the Comptroller to Specification 474,820.
Bleomycin&#39;s affinity for tumorous tissue and its ability to complex with cobalt has lead to its use in vivo as a complex with 57Cobalt. This complex has given excellent tumor images and has been useful for diagnostic purposes. Unfortunately, 57Co has the undesirable property of a 270 day half-life. The present invention provides a bleomycin analog which has a powerful meal-chelating substituent covalently bound to and chemically modifying a bleomycin. However, the inclusion of this chelating substituent in the bleomycin analog does not significantly modify the in vivo biological properties thereof with respect to unmodified bleomycin. The inventive bleomycin analog forms stable chelates with a variety of metal ions, and is particularly useful when labelled with radionuclides having short half-lives. So labelled, the bleomycin analog may be utilized for diagnostic purposes.
FIELD: medicine. SUBSTANCE: the method deals with treating the disfunction of urinary bladder specified by detrusor&#39;s hyperactivity. The method is represented by instillation of anticholinergic preparation containing oxybutinine hydrochloride at physiologically acceptable dosage. The novelty is that this one additionally contains dimexide and aqueous solution of polyvinyl alcohol. Moreover, the mentioned preparation should be injected as a solution at standard volume of 20 ml at single dose in a day to remove all clinical signs of the disease. The method enables to improve transepithelial penetration of oxybutinine through urinary bladder&#39;s mucosa. EFFECT: higher efficiency of therapy. 1 cl, 1 tbl
PURPOSE:To provide a new compound useful for readily producing an amino- substituted spiro compound as an intermediate for synthesis of an antimicrobial compound useful as a medicine. CONSTITUTION:A compound of formula I (R&lt;1&gt; is a benzyl composed of phenyl which may be substituted with a halogen, etc., and methylene, t-butyl, etc.; R&lt;2&gt; is phenyl which may be substituted with a halogen, nitro, etc., a 1 to 6C alkyl, etc.), e.g. 1-benzyloxyacetyl-1-methoxycarbonylcyclopropane. The compound of formula I is obtained, e.g. by reacting a alpha-alkyloxy-beta-ketoester derivative with a compound of formula II (XA and XB are each an atom or a functional group respectively eliminable by a nucleophilic reaction) in a solvent under a basic condition. In addition, a compound of formula VI can be obtained by reducing a compound of formula I in the presence of a metal hydride complex, reacting the resultant compound of formula III with a substitute sulfonyl chloride in a solvent under a basic condition and reacting the obtained compound of formula IV with a compound of formula V (Q is phenyl which may be substituted with a halogen, etc.).
PURPOSE:To obtain a medicine, a cosmetic and a food and drink, containing mallophenone as an active ingredient, having antioxidant activities and useful for preventing and treating adult diseases, malignant articular rheumatism, burn, common acne, dermal stains, etc. CONSTITUTION:This medicine, cosmetic or food and drink contains mallophenone of formula I or its salt as an active ingredient. The mallophenone or its salt can be prepared as an oral or a parenteral product and utilized in the field of the medicine, a quasi-drug, the cosmetic and food and drink by suitably blending the active ingredient with usually used carriers, adjuvants or additives according to a conventional method. The daily dose thereof as the medicine is 2-1000mg and the daily oral intake as a healthy food of a functional food is 5-500mg. The active ingredient has effects on suppression of disorder caused by active oxygen or peroxylipids produced in the living body and is useful for disorder in health or beauty and stabilizing the food and drink and improving the keeping quality thereof. The compound of formula I is obtained by reacting a compound of formula II (Prot is a protecting group) with a diazo compound, methylating the 4&#39;-position and then deprotecting the resultant compound.
The fat-soluble vitamin is extracted from fish oils, fish-liver oils, butter and other milk fats, &amp;c., by converting the fatty material into an insoluble soap, either directly or through the intermediary of a soluble soap, and treating the insoluble soap with an organic solvent.  The access of air during the extraction process should be avoided.  According to the examples (1) a solution of the vitamin is obtained by saponifying cod-liver oil hot or cold with alcoholic calcium or barium hydroxide and filtering the product, or by saponifying the oil with calcium or barium hydroxide under ordinary or increased pressure and treating the product with alcohol or ether; (2) the raw material is saponified hot or cold with alcoholic caustic potash or soda, calcium or barium chloride then added, and the soaps removed by filtration.  In both cases, any calcium or barium hydroxide remaining in the product is precipitated by passing carbon dioxide, and the evaporated filtrate is then treated with ether, benzene or chloroform, which takes up the vitamin leaving behind the glycerin and mineral salts.  Any soap present is removed by conversion into the alkali soap and washing this out with water. Small quantities of fatty acid still remain and these are eliminated by treatment with potassium carbonate, followed if necessary by the addition of dilute silver nitrate solution.  A crude vitamin is obtained which is freed from cholesterol by dissolving it in 85-90 per cent methyl alcohol and allowing the cholesterol to crystallize out.  The properties of the product are described.  The vitamin may conveniently be dissolved in fatty matter or alcohol, or be absorbed by lactose, starch or the like.  The Specification makes reference to the results obtained when cod-liver oil and butter are subjected to hot or cold saponification with various agents and describes the extraction of the vitamin from cod-liver oil by adding oleic acid thereto, extracting with alcohol and freeing the extract from its oleic content.  Specification 227,122 is referred to.
Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer&#39;s disease, Parkinson&#39;s disease, Wilson&#39;s disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and/or post stroke.
The present invention relates to photosensitizers with Aggregation Induced Emission (AIE) properties and high efficiency singlet oxygen generation. They have a maximum absorption peak around 490nm in the visible region with deep red/near infrared emission (&gt; 650 nm). The antibacterial property can be improved by adjusting the number of molecular charges of the AIE photosensitizer. The AIE photosensitizers to which the present invention relates can selectively image and kill bacteria without affecting mammalian cells. Under the irradiation of white light, the AIE photosensitizer with two positive charges has good antibacterial performance on gram-negative bacteria and gram-positive bacteria; in the dark field, two positively charged AIE photosensitizers also have good antimicrobial properties against gram-positive bacteria. AIE photosensitizers with a positive charge are highly potent antibacterial agents against gram-positive bacteria and are highly potent in inhibiting gram-positive bacterial proliferation within mammalian cells in the dark field.
PURPOSE:To obtain the titled compound having immune adjusting actions, growing action on nerve projection of cell and differentiation introducing ability, by reacting a specific sialic acid derivative with cholesterol and hydrolyzing the prepared reaction product. CONSTITUTION:A compound shown by formula I is reacted with cholesterol in a molar ratio of the former to the latter of usually 1:1-5. The reaction is usually carried out in the presence of a catalyst (e.g. silver trifluoromethanesulfonate, etc.) for Koenigs-Knorr reaction in a solvent such as THF, etc., at 20-25 deg.C. Then the prepared compound shown by formula II (one of R&lt;1&gt; and R&lt;2&gt; is -COOCH3 and the other is group shown by formula III) is treated with 1-3N sodium hydroxide solution at 15-25 deg.C for 5-15hr and hydrolyzed to give the aimed compound shown by formula IV (one of R&lt;3&gt; and R&lt;4&gt; is -COONa and the other is group shown by formula III).
A food-grade tableware cleaning agent belongs to the category of surfactants, all components of the food-grade tableware cleaning agent are food materials specified by related national food safety standards, and the food-grade tableware cleaning agent is a genuine edible &#39;detergent&#39;. The cleaning agent is particularly used for cleaning household tableware, washing hands of infants and food operators, cleaning meat surfaces, and cleaning chopping boards and cutting tools for processing food. The product not only achieves the basic aims of removing oil stains, sterilizing and inhibiting bacteria, having no residual hazard, natural degradation and the like, but also has the advantages of mild cleaning and skin protection, little foam, easy cleaning, water saving and environment protection and the like. The cleaning time is prolonged to make up for the deficiency that the decontamination capability of the product is weaker than that of the daily chemical products, and the washing time can be saved due to the advantages of less foam, easy washing, no residue and harm and the like. The cost of water saved by flushing is reduced, the cost increased by most raw materials can be reduced, and water resources can be saved. All the components are products of industrial production, and the method is suitable for large-scale batch production and convenient to use.
Human or animal bones are used to house and nurture other useful tissues. Once inside the bones, the transferred cells may become attached to the bone, and the blood vessels within the bone provide nutrition. The transferred cells or tissues can be injected as a solution of individual cells or small clumps of cells. Large numbers of cells supported with an extracellular matrix scaffold can be surgically implanted or injected. The extracellular matrix can be synthetic, resorbing, or derived from biologic sources. To assist with transfer, the cells or tissue may be contained in a bag before being placed in the bone. The non-bone materials may either be removed from the bone following sufficient growth and nourishment, or the biologic materials may remain in place to provide one or more desirable functions. For example, a bone&#39;s access to the blood stream should help the islet cells monitor blood glucose, and release insulin into the blood stream.
The present invention discloses wine for reducing blood fat and blood pressure, which relates to health wine. The present invention aims to solve the problem that the existing health wine has no health care action on pathological symptoms, such as hyperlipoidemia, hypertension, etc. The present invention is prepared from (by weight percentage) 60 to 99% of pure grain spirit and 1 to 40% of heart saving vegetable juice. The preparation method of the present invention comprises: the pure grain spirit is taken, the alcohol concentration of the pure grain spirit is from 40 to 60%((namely 40 to 60 %Vol), fresh heart saving vegetables are washed clean, and water is drained; juice is extracted from the fresh heart saving vegetables and is filtered, and the pure grain spirit and the heart saving vegetable juice are evenly mixed. The heart saving vegetables of the present invention have the efficiency of blood fat reduction and blood pressure reduction, and the heart saving vegetables are blended with the spirit; on one hand, the health care action of blood fat reduction and blood pressure reduction at the time of drinking can be achieved, and on the other hand, because the heart saving vegetables have cool nature and flavor, the heart saving vegetables and the spirit with the nature and flavor of great heat can learn from others&#39; strengths to make up for weaknesses. Because the alcohol can promote the synthesis of endogenous cholesterin and triglyceride to cause blood fat to rise, the ingredients of the heart saving vegetables are added in the spirit, and can counteract the action of blood fat rise of the spirit.
The present invention relates to a veterinary medicine composition for preventing and curing coccidiosis. The final product is in a henna liquid form, which contains I&lt;-&gt;0.01 to 1.0%(mol/ml) of iodine ions, 0.5 to 50%(V/V) of lactic acid, 0.1 to 40%(V/V) of tannic acid, and water as the rest. The preparation method for the composition comprises the steps: preparing iodine ion I&lt;-&gt; ionization induction liquid, preparing iodine ion I&lt;-&gt; solution, treating by lactic acid, treating by tannic acid and adding water to a constant volume. The composition kills cells in coccidian and can effectively and thoroughly kill coccidium forms at every development stages of the coccidium life history. Since the integrated synergistic action of the contained iodine ions I&lt;-&gt;, lactic acid and tannic acid, the present invention can repair damaged mucosae of intestinal tracts, enhance livestock organism resistance, and restore the livestock growth ability without harm to livestock organisms. In conclusion, the composition is a green environmental protection medicine and is brought in line with WTO, with no prohibited drugs or components, no toxic and side effects, no residual drug, no drug holiday, no drug resistance, no cross drug resistance, quick and thorough therapeutic effects and no recurrence.
Novel steroids of the formulae &lt;FORM:1038275/C2/1&gt; and &lt;FORM:1038275/C2/2&gt; (wherein R is N3 or NR1R11 is hydrogen or C1- 4 alkyl and R11 is hydrogen, C1- 4 alkyl or acyl) are prepared by treating steroids of the formula &lt;FORM:1038275/C2/3&gt; (wherein R1 is as defined above and R11 is C1- 4 alkyl, phenyl or tolyl) with 5 to 40 moles per mole of the steroid of an azide AN3 (wherein A is sodium, potassium, lithium or tetraalkylammonium) in an inert, aprotic, nucleophilic solvent having a dielectric constant of at least 10, at a temperature between 50 DEG  and 120 DEG  C. for at least 30 minutes, and isolating from the reaction mixture the formed 3a -azido-androst-5-ene and 6a -azido-3a ,5a -cycloandrostane, and, when required, reducing these to the corresponding amino compounds. The acylamino, alkylamino, dialkylamino and N-acyl-N-alkylamino compounds are prepared by standard alkylation and acylation procedures.  In the azide-forming process, when the desired product is the 6a -compound the preferred reaction medium is N-methyl-acetamide, while when the desired product is the 3a -compound, the preferred medium is dimethylsulphoxide.  The azido compounds may be separated by diluting the reaction mixture with water, extracting with ether, drying and evaporating the extract, separating the 3a -azido compound by crystallization from an alcohol and water, and isolating the 6a -azido compound from the mother liquor by chromatography on a magnesium silicate column.  Ester products may be saponified to the free acids which in turn may be esterified.  Steroids of the third general formula above are prepared from the corresponding 3b -hydroxy steroids and sulphonyl halides.